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BACKGROUND: A transcription regulatory complex (TRC) that includes Ets1, Ets2, PEA3 and b-catenin/T-cell factors regulates
osteopontin (OPN) that is implicated in colorectal cancer (CRC) dissemination. The consistency of OPN transcriptional control
between primary CRC and metastases is unclear. This study investigates expression and prognostic significance of the OPN–TRC in
primary human CRC and associated colorectal liver metastases (CRLM).
METHODS: Osteopontin–TRC factors were assayed by digital microscopy in 38 primary CRCs and matched CRLM specimens and
assessed against clinical prognosis.
RESULTS: In primary CRC, OPN expression intensity correlated with that of its co-activators, PEA3 (r¼ 0.600; Po0.01), Ets1
(r¼ 0.552; Po0.01), Ets2 (r¼ 0.521; Po0.01) and had prognostic significance. Osteopontin intensity in primary CRC inversely
correlated with the interval between diagnosis and resection of CRLM. Overall OPN intensity was lower in CRLM than primary CRC
and correlations with co-activators were weaker, for example, Ets1 (P¼ 0.047), PEA3 (P¼ 0.022) or nonsignificant (Ets2). The ratio
of OPN expression in CRLM vs primary CRC had prognostic significance.
CONCLUSION: This study supports transcriptional control of OPN by known coregulators in both primary and secondary CRC.
Weaker associations in CRLM suggest involvement of other unknown factors possibly from the liver microenvironment or resulting
from additional genetic or epigenetic changes that drive tumour metastatic capability in OPN transcriptional control.
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Successful establishment of metastases from circulating tumour
cells requires integration of cell-autonomous oncogenic signalling
with external cues from the specific tissue microenvironment of
target organs (Fidler, 2002). Osteopontin (OPN) promotes inva-
siveness of colorectal cancer (CRC) (Irby et al, 2004) and other
solid tumours (El-Tanani et al, 2006) and is a lead marker of
human CRC progression (Agrawal et al, 2002; Eschrich et al, 2005).
Osteopontin is regulated by Ets transcription factors partly by
specific binding to the OPN promoter region (Sato et al, 1998) and
partly through crosstalk with Wnt and other signalling pathways
(El-Tanani et al, 2004). Combinatorial effects of Ets-1, Ets-2, PEA3
and b-catenin/T-cell factors (b-catenin/Tcfs) enhance OPN
expression (El-Tanani et al, 2004) although unbound Tcf-4 may
act as a transcriptional OPN repressor (El-Tanani et al, 2006). In
primary CRC, molecular consequences of the initiating adenoma-
tous polyposis coli mutation (Morin et al, 1997) include
hyperactivation of b-catenin/Tcf signalling (Polakis, 2000) that
upregulates PEA3 (Liu et al, 2004). This deregulated signalling may
contribute to OPN overexpression (El-Tanani et al, 2004).
In addition to the molecular consequences of initiating
mutations, the gene expression profiles of metastatic cells may
be influenced by their supporting microenvironment in target
organs (Nakamura et al, 2007). The consistency of the OPN-
regulatory cassette between primary human CRC and related liver
metastases, however, remains unclear. This issue has practical
importance because surgery for liver metastases may be combined
with a range of other therapeutic modalities (Garden et al, 2006)
that could be guided by molecular profiling. Here, we assess
expression and prognostic relevance of OPN-regulatory networks
by immunohistochemistry and digital microscopy, in paired
human primary CRCs and liver metastases.
PATIENTS AND METHODS
Patients
The study included 38 consecutive patients who underwent liver
resection for colorectal liver metastases (CRLM) at the Mater
Infirmorum Hospital Belfast between 1994 and 2003, for whom
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sufficient archive tissue was available. Clinicopathological char-
acteristics were recorded including age, sex, site of colonic primary
tumour, TNM classification and Duke’s stage, date of colonic
surgery, date of liver resection, number and segmental location of
liver metastases, size of the largest liver metastasis, type of liver
resection (left vs right, extended vs standard, anatomical vs non-
anatomical atypical), resection margin status (R0 or other),
immediate post-operative course (blood loss, blood transfusion,
remnant liver function, extrahepatic organ failure, in-hospital
mortality), details of adjuvant chemotherapy and date of death.
Patients classified as Duke’s D presented with synchronous
metastases. Those with classification Duke’s A to C developed
metachronous metastases.
Ethical approval
This study was approved by the Northern Ireland Research Ethics
Committee.
Immunohistochemistry
Archived formalin-fixed paraffin-embedded tissue blocks from the
primary colon resection specimen and the matching resected
CRLM were sectioned (5 mm), mounted on APS-coated slides and
anonymised by a coding system that preserved the within-patient
matched-pair design. Immunohistochemical staining was auto-
mated on a DAKO autostainer (DAKO, Cambridgeshire, UK)
through standard dewaxing, blocking, staining and washing
protocols. Antigen retrieval was performed by microwaving in
citrate buffer at high power for 10min. Consecutive sections were
stained with antibodies (at 1:100 dilution) to the following
proteins: OPN (MAb MBIII B10 mouse/hybridoma, DHSB,
University of Iowa, USA); b-catenin (H-102, sc-7199, Santa Cruz
Biotechnology, Santa Cruz, CA, USA); Tcf4 (H-125, sc-13027,
Santa Cruz Biotechnology); Ets-1 (H-150, sc-22802, Santa Cruz
Biotechnology); Ets-2 (H-140, sc-22803, Santa Cruz Biotechno-
logy); and PEA3 (H-120, sc-22806, Santa Cruz Biotechnology) or
negative control where no primary antibody was used. Secondary
visualisation was performed for all sections (including the no
primary antibody controls), using DAKO Envision Plus HRP Kits
(K4007, DAKO) according to the manufacturer’s instructions.
Digital assessment of gene expression and data analysis
Slides were scanned digitally using an Aperio Scanscope CS2
(Aperio Technologies Inc., Vista, CA, USA) at  40 objective
magnification. Each slide was scanned in its entirety and stored as
a jpeg format compressed tiff (svs) file (approximately 0.5 Gb per
slide). Slide images were viewed using ImageScope (Aperio
Technologies Inc.) and annotated digitally by accurately tracing
OPN
Annotated
x40 x200 x500 x2000
Figure 1 Digital expression analysis of OPN. An automated positive pixel count algorithm was applied to the digitally scanned annotated images. The
image shown is a section of colorectal primary tumour stained for OPN visualised with DAB.
Table 1 Details of colorectal primary tumours
Number %
Site of colorectal primary Right colon 12 31.6
Left colon 13 34.2
Rectum 13 34.2
Duke’s stage A 0 0.0
B 5 13.2
C 13 34.2
(D)a 15 39.5
TNM classification pT1 0 0.0
(colon specimen) pT2 0 0.0
pT3 12 31.6
pT4 7 18.4
TNM:T status not formally
reported
19 50.0
N0 7 18.4
N1 6 15.8
N2 6 15.8
TNM:N status not formally
reported
19 50.0
M0 18 47.4
M1 20 52.6
Abbreviation: TNM¼ tumour–node–metastases.
aPresented with synchronous metastases.
Table 2 Details of resected liver metastases
Number %
Liver resection Non-anatomical resection 11 28.9
Left hepatectomy 4 10.5
Right hepatectomy 20 52.6
Extended left hepatectomy 1 2.6
Extended right hepatectomy 2 5.3
Number of liver
metastases
1 26 68.4
2 3 7.9
3 3 7.9
4 2 5.3
44 4 10.5
Size of largest liver Median 5 (IQR 4 to 6)
metastasis (cm) Mode 4
Liver resection margin R0 32 84.0
status R1 6 16.0
Nearest involved Median 9 (IQR 5 to 10)
margin (mm) Mode 10
Abbreviation: IQR¼ interquartile range.
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Figure 2 Osteopontin and coregulators in primary CRC and CRLM matched pairs. Consecutive sections of colorectal primary tumour and liver
metastasis, illustrating the raw scanned image and the positive pixel count for each primary antibody. Line diagrams show the difference between primary
tumour and matched liver metastasis for each patient.
Table 3 Magnitude of differential expression of OPN and coregulators between primary CRC and matched liver metastases
Colon (% positivity) Liver (% positivity) Matched pair difference Paired t-test significance
Negative control 2.8±0.3 3.2±0.4 0.5±0.5 0.338
OPN 24.4±2.4 11.7±1.1 12.7±2.4 o0.001
Ets1 28.6±2.8 59.4±2.2 30.8±3.2 o0.001
Ets2 57.8±2.0 64.2±2.7 6.4±3.4 0.07
PEA3 25.4±2.0 44.2±3.1 18.8±3.3 o0.001
Tcf4 37.3±3.7 48.4±2.7 11.1±4.0 0.009
b-catenin 52.7±2.0 62.6±3.1 9.9±3.3 0.006
b-Cat/Tcf4 ratio 70.8±6.9 79.7±5.1 8.9±8.1 0.283
Abbreviations: CRC¼ colorectal cancer; OPN¼ osteopontin.
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the area of interest corresponding to tumour tissue. The annotated
area was segmented using pixel density threshold analysis
developed in-house and run within the ImageScope software
(Figure 1). This used custom parameters detailed in Supplemen-
tary Table S1. The number and staining intensity of each pixel
within the area of interest was calculated and exported for analysis
via Microsoft Excel. Positivity was defined as the number of pixels
exceeding the set threshold for staining intensity divided by the
total number of pixels within the annotated area, expressed as a
proportion. Intensity of staining was a continuous scale variable
defined as the sum of staining intensities of all pixels within the
annotated area. Subsequent statistical analysis and comparison
with clinicopathological data was performed using SPSS v14.0
(SPSS Inc., Chicago, IL, USA). The relationship of immunohisto-
chemical covariates (expressed as the ratio of staining intensity
between colon and liver), clinical and pathological features to
survival after hepatic resection was investigated by a Cox
proportionate hazard model.
RESULTS
A total of 26 patients were male and 12 were female with median
age of 62.1 years at colectomy (interquartile range, 12.8 years). Pre-
operative liver synthetic function (albumin and prothrombin time)
were within the normal reference range and all patients were
seronegative for hepatitis B and C. Details of tumour primary site,
Duke’s classification and TNM stage are presented in Table 1. The
median interval between colectomy for primary CRC and liver
resection for metastatic disease was 1.51 years (95% CI: 0.84, 2.18
years). The site, number, size, resection margin of liver metastases
are presented in Table 2. The median survival time from liver
resection was 3.90 years (95% CI: 3.2, 4.6 years) and from
colectomy was 4.95 years (95% CI: 4.05, 5.85 years). In all, 20% of
patients remained free of detectable cancer at 5 years after liver
resection.
Expression of OPN and its transcriptional regulatory complex
including Ets1, Ets2, PEA3, Tcf4 and b-catenin were detected
by immunohistochemistry and digital scanning microscopy
(Figures 1 and 2). Positive correlations between OPN intensity
and that of PEA3 (r¼ 0.600; Po0.01), Ets1 (r¼ 0.552; Po0.01),
Ets2 (r¼ 0.521; Po0.01) were observed in primary tumours.
Osteopontin positivity was generally lower in CRLM in compar-
ison with that of the primary CRC (Po0.001; Figure 2, Table 3).
The intensity of OPN expression in primary CRCs inversely
correlated with the disease-free interval between colectomy and
liver resection for metastases (Pearson’s correlation coefficient,
r¼0.123, P¼ 0.045; Figure 3). Conversely, expression of each
component of the OPN regulatory complex including Ets factors,
Tcf4 and b-catenin was higher in CRLM than in primary tumours
(Table 3). Weakly positive correlations were observed between
OPN, Ets1 (P¼ 0.047), PEA3 (P¼ 0.022), Tcf4 (P¼ 0.028) but not
Ets2 in CRLM. In the majority of matched pairs, OPN expression
was decreased or unchanged in the liver metastasis compared with
the primary tumour, whereas Ets1, Ets2, PEA3, Tcf4 and b-catenin
were predominantly increased (Table 4). The prognostic signifi-
cance of differential expression of OPN and components of its
regulatory complex between primary and secondary tumour was
explored by Cox analysis. The ratio of OPN expression between
paired samples of primary CRC and CRLM had prognostic
significance after liver resection (Table 5).
DISCUSSION
Osteopontin is an important pro-metastasis gene with complex
molecular regulation making its study in human primary and
metastatic CRC a particular interest. Ets1, Ets2, PEA3 and Tcf
factors bind to specific domains in the OPN promoter (El-Tanani
et al, 2004, 2010). However, the identification of defined regulatory
domains within the OPN promoter is insufficient evidence for
involvement of single or combined transcriptional regulators in
OPN-driven neoplastic progression. For example, PEA3 is a potent
activator of pro-oncogenic OPN (El-Tanani et al, 2004) but may
also inhibit breast cancer progression (Xing et al, 2000). Hence,
interaction of coregulators with OPN may be context-specific.
Approximately 20–25% of CRC patients will have detectable
liver secondaries at the time of the initial diagnosis and a further
40–50% of patients will typically develop hepatic metastases
within 3 years of colectomy (Stangl et al, 1994). In this study,
patients predominantly had Duke’s C and D CRCs at presentation
and had a median interval of 18 months between colectomy and
liver resection. In this poor prognostic cohort, OPN and its
coregulators including Ets factors, b-catenin and Tcf4 were
detected in primary CRCs and liver metastases by digital
microscopy. This method assesses the number of positive pixels
as well as the intensity of immunohistochemical staining in
annotated areas of histological tissue sections, using specific
algorithms (Steinberg and Ali, 2001; Costello et al, 2003; Molnar
et al, 2003). We manually annotated the area of interest
corresponding to tumour tissue for digital microscopic assess-
ment. This remains the most accurate method currently available
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Figure 3 Osteopontin intensity in primary CRC vs interval to liver
resection. Osteopontin expression in primary CRC inversely correlates
with interval between colectomy and liver resection for metastases
(P¼ 0.045; Pearson’s product moment test).
Table 4 Direction of change in protein expression between matched
colorectal primary and liver metastasis (number of patients)
Increased
positivity in
CRLM
Decreased
positivity in
CRLM
Unchanged in
CRLM
OPN 0 17 21
Ets1 28 0 10
Ets2 13 7 18
PEA3 23 4 11
Tcf4 15 5 18
b-catenin 18 5 15
b-Cat/Tcf4 ratio 8 10 20
Abbreviations: CRLM¼ colorectal liver metastases; OPN¼ osteopontin.
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and ensures that marker expression is predominantly confined to
tumour cells. Although some background marker expression is
inevitable in non-tumour cell fractions of primary and secondary
CRC, such quantitative image analysis has superior reproducibility
and consistency over observer scoring, in immunohistochemical
assays (Ellis et al, 2005). By this method, we found that the
intensity of OPN expression in primary CRCs, correlated directly
with that of key OPN co-activators including PEA3, Ets1 and Ets2
and inversely correlated with the interval until liver resection for
CRLM. These findings support prognostic relevance of OPN in
CRC, as previously reported (Agrawal et al, 2002). Furthermore,
our study provides the scientific foundation for further funda-
mental investigations in model systems, which may accelerate
validation of OPN and/or coregulators as molecular targets for
therapy.
Signals from an inhospitable tissue microenvironment may
influence the growth of metastatic tumour (Fidler, 2002; Nakamura
et al, 2007). In this study, expression of OPN co-activators
including Ets1, Ets2, PEA3 and b-catenin were increased in the
majority of CRLM vs primary CRC. However, these changes were
not accompanied by any relative increase in OPN expression,
which was unchanged in 21 patients and decreased in 17 CRLMs vs
primary CRCs. Tcf4 is a potential suppressor of OPN when not
complexed with b-catenin (El-Tanani et al, 2006) and was also
increased in CRLM in comparison with primary CRC. However, no
significant correlations were observed between Tcf4 and OPN in
CRLM. It appears unlikely that Tcf4 alone would have overcome
the combinatorial enhancing effects of Ets1, Ets2, PEA3 and
b-catenin, on OPN expression in CRLM. Although correlations
were observed between OPN expression and that of its co-
activators in liver metastases, these were weaker than those of
primary CRC. Cox analysis demonstrated that the ratio of OPN
expression in the primary tumour to that in CRLM (colon to liver
ratio) had prognostic significance.
Taken together, our study shows expression differences of OPN
and its coregulators between primary CRC and liver metastases.
The weaker correlations between OPN and its coregulators in
CRLM suggest context specificity of OPN transcriptional control.
Unknown signals from the organ microenvironment or additional
genetic or epigenetic changes that accumulate in tumour cells as
they acquire metastatic capability may also influence OPN
regulation, implicated in progression of tumour growth.
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